XML 73 R58.htm IDEA: XBRL DOCUMENT v3.6.0.2
Intangible Assets (Narrative) (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Jul. 07, 2016
Dec. 31, 2016
Aug. 31, 2016
Dec. 31, 2014
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]                
Proceeds from sale of business             $ 110,717 $ 0
Pre-tax gain (loss) on sale         $ 3,405 $ 0 $ (51,552) $ 0
Purchased amortizable intangible assets, weighted average remaining period             12 years 1 month 6 days  
Amortization expense         4,500   $ 14,412  
Minimum                
Finite-Lived Intangible Assets [Line Items]                
Intangible assets, useful lives             10 years  
Maximum                
Finite-Lived Intangible Assets [Line Items]                
Intangible assets, useful lives             30 years  
North American OTC Healthcare | Disposed of by sale                
Finite-Lived Intangible Assets [Line Items]                
Pre-tax gain (loss) on sale         $ (51,600)      
Cough and Cold, Dermatologicals, and Gastrointestinal Products Group | North American OTC Healthcare | Pediacare, New Skin and Fiber Choice | Disposed of by sale                
Finite-Lived Intangible Assets [Line Items]                
Indefinite-lived intangible assets, period decrease $ 37,200              
Disposal group, consideration, excluding costs of inventory 40,000              
Proceeds from sale of business 40,100              
Finite-lived intangible assets, reclassified to assets held for sale 54,000              
Pre-tax gain (loss) on sale $ (56,146)           $ (56,146)  
Cough and Cold, Dermatologicals, and Gastrointestinal Products Group | North American OTC Healthcare | Dermoplast | Disposed of by sale                
Finite-Lived Intangible Assets [Line Items]                
Indefinite-lived intangible assets, period decrease   $ 31,000            
Proceeds from sale of business   48,400            
Cough and Cold, Dermatologicals, and Gastrointestinal Products Group | North American OTC Healthcare | e.p.t. | Disposed of by sale                
Finite-Lived Intangible Assets [Line Items]                
Indefinite-lived intangible assets, period decrease   $ 14,800            
Trademarks                
Finite-Lived Intangible Assets [Line Items]                
Indefinite-lived intangible assets, period decrease     $ 9,000          
Comet Brand                
Finite-Lived Intangible Assets [Line Items]                
Proceeds from divestitures     11,000 $ 10,000     $ 1,000  
Gain on sale of intangible assets     $ 1,200